[go: up one dir, main page]

WO2000001692A1 - Sels de paroxetine - Google Patents

Sels de paroxetine Download PDF

Info

Publication number
WO2000001692A1
WO2000001692A1 PCT/EP1999/004543 EP9904543W WO0001692A1 WO 2000001692 A1 WO2000001692 A1 WO 2000001692A1 EP 9904543 W EP9904543 W EP 9904543W WO 0001692 A1 WO0001692 A1 WO 0001692A1
Authority
WO
WIPO (PCT)
Prior art keywords
acid
benzoic
phenyl
carboxylic
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1999/004543
Other languages
English (en)
Inventor
Victor Witold Jacewicz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AU49039/99A priority Critical patent/AU4903999A/en
Priority to CA002336470A priority patent/CA2336470A1/fr
Priority to APAP/P/2000/002017A priority patent/AP2000002017A0/en
Priority to JP2000558095A priority patent/JP2002519421A/ja
Priority to BR9911679-0A priority patent/BR9911679A/pt
Priority to SK2024-2000A priority patent/SK20242000A3/sk
Priority to EP99932772A priority patent/EP1091958A1/fr
Priority to IL14038599A priority patent/IL140385A0/xx
Priority to EA200100098A priority patent/EA200100098A1/ru
Priority to PL99345365A priority patent/PL345365A1/xx
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Priority to KR1020007015100A priority patent/KR20010053337A/ko
Publication of WO2000001692A1 publication Critical patent/WO2000001692A1/fr
Priority to NO20006547A priority patent/NO20006547L/no
Anticipated expiration legal-status Critical
Priority to BG105204A priority patent/BG105204A/xx
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • the present invention relates to novel compounds, to processes for preparing them and to their use in treating medical disorders.
  • the present invention provides novel salts of paroxetine which may be used as an alternative to the currently marketed hydrochloride, or as an intermediate in the preparation of the hydrochloride.
  • 2-methylthiobenzimidazolesulfonic acid phenaceturic acid alpha, beta-dibromocinnamic acid o-trifluoromethyl-alpha-acetamidocinnamic acid boc-d-alpha-amino-gamma-(4-methylbenzylmercapto)-butyric acid n-alpha-(benzyloxycarbonyl)-d-aspartic acid
  • 4-(4-methoxyphenyl)thiophene-2-carboxylic acid 4-(4-methylbenzylideneamino)salicylic acid (2.2,2-trichloro-l-(3-p-tolyl-thioureido)-ethyl)-carbamic acid (s)-(+)-alpha-hydroxy-l ,3-dioxo-2-isoindolinebutyric acid 2.2'-( 1 ,2-ethanediyl)bis[5-aminobenzenesulfonic acid] 4'-nitromaleanilic acid 3.5-diisopropoxybenzoic acid n-(4-(4-chloro-phenoxy)-phenyl)-phthalamic acid benzoylamino-phenyl-acetic acid 4-chloro-3-nitrobenzoic acid 4-methylphthalic acid beta-(2-acetoxyphenyl)propionic acid (3-fluorophenyl)phosphonic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)

Abstract

L'invention concerne des composés de pipéridine, des procédés de préparation de ces derniers, des compositions pharmaceutiques les contenant et leur utilisation à des fins thérapeutiques.
PCT/EP1999/004543 1998-07-02 1999-06-30 Sels de paroxetine Ceased WO2000001692A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
EA200100098A EA200100098A1 (ru) 1998-07-02 1999-06-30 Соли пароксетина
APAP/P/2000/002017A AP2000002017A0 (en) 1998-07-02 1999-06-30 Salts of paroxetine.
JP2000558095A JP2002519421A (ja) 1998-07-02 1999-06-30 パロキセチンの塩
BR9911679-0A BR9911679A (pt) 1998-07-02 1999-06-30 Sais de paroxetina
SK2024-2000A SK20242000A3 (sk) 1998-07-02 1999-06-30 Paroxetínová soľ, spôsob jej prípravy a jej použitie
EP99932772A EP1091958A1 (fr) 1998-07-02 1999-06-30 Sels de paroxetine
IL14038599A IL140385A0 (en) 1998-07-02 1999-06-30 Salts of paroxetine
AU49039/99A AU4903999A (en) 1998-07-02 1999-06-30 Salts of paroxetine
CA002336470A CA2336470A1 (fr) 1998-07-02 1999-06-30 Sels de paroxetine
PL99345365A PL345365A1 (en) 1998-07-02 1999-06-30 Salts of paroxetine
KR1020007015100A KR20010053337A (ko) 1998-07-02 1999-06-30 파록세틴 염
NO20006547A NO20006547L (no) 1998-07-02 2000-12-21 Salter av paroxetine
BG105204A BG105204A (en) 1998-07-02 2001-01-31 Salts of paroxetine

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9814316.7 1998-07-02
GBGB9814316.7A GB9814316D0 (en) 1998-07-02 1998-07-02 Novel compounds

Publications (1)

Publication Number Publication Date
WO2000001692A1 true WO2000001692A1 (fr) 2000-01-13

Family

ID=10834803

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/004543 Ceased WO2000001692A1 (fr) 1998-07-02 1999-06-30 Sels de paroxetine

Country Status (21)

Country Link
EP (1) EP1091958A1 (fr)
JP (1) JP2002519421A (fr)
KR (1) KR20010053337A (fr)
CN (1) CN1314906A (fr)
AP (1) AP2000002017A0 (fr)
AU (2) AU4903999A (fr)
BG (1) BG105204A (fr)
BR (1) BR9911679A (fr)
CA (1) CA2336470A1 (fr)
CZ (1) CZ20004923A3 (fr)
EA (1) EA200100098A1 (fr)
GB (1) GB9814316D0 (fr)
HU (1) HUP0103712A3 (fr)
ID (1) ID27766A (fr)
IL (1) IL140385A0 (fr)
NO (1) NO20006547L (fr)
PL (1) PL345365A1 (fr)
SK (1) SK20242000A3 (fr)
TR (1) TR200100055T2 (fr)
WO (1) WO2000001692A1 (fr)
ZA (2) ZA992899B (fr)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006033505A1 (fr) * 2004-09-21 2006-03-30 Chong Kun Dang Pharmaceutical Corp. Sels derives de cholate de paroxetine ou d'acide cholique, et composition comportant de la paroxetine et de l'acide cholique ou des derives de l'acide cholique
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
US7595342B2 (en) 2003-05-07 2009-09-29 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
EP2266584A2 (fr) 2003-05-07 2010-12-29 Osteologix A/S Composition contenant du strontium et de la vitamine D pour la prophylaxie et/ou le traitement de pathologies des cartilages et/ou des os
US8609616B2 (en) 2004-02-26 2013-12-17 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
CN111337460A (zh) * 2018-12-18 2020-06-26 中国科学院大连化学物理研究所 一种高稳定性Halo-tag探针及其合成和生物应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109212055B (zh) * 2018-08-19 2021-05-07 丁立平 一种测定饮用水中四种痕量单卤代苯乙酸的气相色谱-质谱联用法
CN109342633B (zh) * 2018-11-27 2020-10-02 北京市化工职业病防治院 尿液中苯、甲苯和二甲苯代谢物的检测方法
CN116283778B (zh) * 2023-02-23 2025-08-29 江苏理工学院 一种吡唑羧酸类化合物及其制备方法和应用
US20250091996A1 (en) 2023-09-15 2025-03-20 King Faisal University 2-(1h-imidazole-1-carbonyl)benzoic acid as an anticancer compound

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188081A2 (fr) * 1984-12-04 1986-07-23 Novo Nordisk A/S Utilisation de paroxétine pour l'obtention d'un medicament pour le traitement del'obèsitè
EP0223403A2 (fr) * 1985-10-25 1987-05-27 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
EP0810224A1 (fr) * 1996-05-30 1997-12-03 Asahi Glass Company Ltd. Procédé de préparation de l'hydrochlorure de paroxétine amorphe
WO1998001424A1 (fr) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. Derives de n-benzylpiperidine et de tetrahydropyridine
WO1998056787A1 (fr) * 1997-06-10 1998-12-17 Synthon B.V. Composes 4-phenylpiperidine
WO1999040084A1 (fr) * 1998-02-06 1999-08-12 Smithkline Beecham Plc Sels de paroxetine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188081A2 (fr) * 1984-12-04 1986-07-23 Novo Nordisk A/S Utilisation de paroxétine pour l'obtention d'un medicament pour le traitement del'obèsitè
EP0223403A2 (fr) * 1985-10-25 1987-05-27 Beecham Group Plc Dérivé de pipéridine, sa préparation et son utilisation comme médicament
EP0810224A1 (fr) * 1996-05-30 1997-12-03 Asahi Glass Company Ltd. Procédé de préparation de l'hydrochlorure de paroxétine amorphe
WO1998001424A1 (fr) * 1996-07-08 1998-01-15 Richter Gedeon Vegyészeti Gyár Rt. Derives de n-benzylpiperidine et de tetrahydropyridine
WO1998056787A1 (fr) * 1997-06-10 1998-12-17 Synthon B.V. Composes 4-phenylpiperidine
WO1999040084A1 (fr) * 1998-02-06 1999-08-12 Smithkline Beecham Plc Sels de paroxetine

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7595342B2 (en) 2003-05-07 2009-09-29 Osteologix A/S Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions
EP2266585A2 (fr) 2003-05-07 2010-12-29 Osteologix A/S Sels de strontium hydrosolubles pour le traitement des d'affections de cartilage et/ou d'os
EP2266584A2 (fr) 2003-05-07 2010-12-29 Osteologix A/S Composition contenant du strontium et de la vitamine D pour la prophylaxie et/ou le traitement de pathologies des cartilages et/ou des os
US8609616B2 (en) 2004-02-26 2013-12-17 Osteologix A/S Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions
US7589235B2 (en) 2004-05-06 2009-09-15 Osteologix, A/S High yield and rapid synthesis methods for producing metallo-organic salts
US8183409B2 (en) 2004-05-06 2012-05-22 Osteologix A/S High yield and rapid synthesis methods for producing metallo-organic salts
WO2006033505A1 (fr) * 2004-09-21 2006-03-30 Chong Kun Dang Pharmaceutical Corp. Sels derives de cholate de paroxetine ou d'acide cholique, et composition comportant de la paroxetine et de l'acide cholique ou des derives de l'acide cholique
US7229980B2 (en) 2004-09-21 2007-06-12 Chong Kun Dang Pharmaceutical Corp. Paroxetine cholate or cholic acid derivative salts, and composition comprising paroxetine and cholic acid or derivative thereof
RU2337919C2 (ru) * 2004-09-21 2008-11-10 Чонг Кун Данг Фармасьютикл Корп. Пароксетин холат или соли производных холевой кислоты и композиция, содержащая пароксетин и холевую кислоту или производные холевой кислоты
US9873667B2 (en) 2006-07-27 2018-01-23 Emisphere Technologies Inc. Arylsulfanyl compounds and compositions for delivering active agents
CN111337460A (zh) * 2018-12-18 2020-06-26 中国科学院大连化学物理研究所 一种高稳定性Halo-tag探针及其合成和生物应用
CN111337460B (zh) * 2018-12-18 2021-09-17 中国科学院大连化学物理研究所 一种高稳定性Halo-tag探针及其合成和生物应用

Also Published As

Publication number Publication date
EA200100098A1 (ru) 2001-08-27
ID27766A (id) 2001-04-26
BR9911679A (pt) 2002-01-29
AU4903999A (en) 2000-01-24
CN1314906A (zh) 2001-09-26
ZA200100020B (en) 2002-03-25
AP2000002017A0 (en) 2000-12-31
CZ20004923A3 (cs) 2001-08-15
TR200100055T2 (tr) 2001-07-23
ZA992899B (en) 2000-03-29
KR20010053337A (ko) 2001-06-25
PL345365A1 (en) 2001-12-17
IL140385A0 (en) 2002-02-10
CA2336470A1 (fr) 2000-01-13
HUP0103712A3 (en) 2002-09-30
NO20006547L (no) 2001-02-12
NO20006547D0 (no) 2000-12-21
EP1091958A1 (fr) 2001-04-18
GB9814316D0 (en) 1998-09-02
HUP0103712A2 (hu) 2002-05-29
JP2002519421A (ja) 2002-07-02
BG105204A (en) 2001-11-30
SK20242000A3 (sk) 2001-07-10
AU2002100370A4 (en) 2002-06-06

Similar Documents

Publication Publication Date Title
WO2000001692A1 (fr) Sels de paroxetine
AU773445B2 (en) Substituted phenylpropanoic acid derivatives as agonists to human peroxisome proliferator-activated receptor (PPAR) alpha
DE69527798T2 (de) Substituierte 4-biarylbutyr-oder 5-biarylpentasäuren und derivate als matrix metalloprotease inhibitoren
TW199152B (fr)
AU2008222810A1 (en) PPAR active compounds
JP2006504767A (ja) フェニル化合物
JP4846978B2 (ja) タンパク質チロシンホスファターゼのオキシンドールヒドラジンモジュレータ
WO2001081312A2 (fr) Methode de traitement se basant sur l'utilisation de derives de phenyle et de biaryle comme inhibiteurs de prostaglandine e
AU2007225208A1 (en) Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
CN101284773A (zh) 羧酸衍生物及以它为活性成分的药剂
HU183085B (en) Process for preparing new phenoxy-alkyl-carboxylic acid derivatives and pharmaceutical compositions containing thereof
JP2010504286A (ja) スフィンゴシン−１−リン酸（ｓ１ｐ）受容体アゴニスト及び／又はアンタゴニスト生物活性を有するヘテロ芳香族化合物
TW200521108A (en) Compounds having lysophosphatidic acid receptor(LPA)-antagonizing effect and their use
WO2005012280A1 (fr) Alkynylaryl-carboxamides
JPH11500748A (ja) Ｃｏｘ−２阻害剤のプロドラッグとしての３，４−ジアリール−２−ヒドロキシ−２，５−ジヒドロフラン
WO2004065365A1 (fr) Derives de 8-azaprostalangine et utilisations de ces derives en tant que medicaments
DE69030202T2 (de) Phenylalkan(en)-Säuren mit Leukotrien B4 antagonistischer Wirkung
JP6310931B2 (ja) Ｇｐｒ１２０アゴニストとしてのチオアリール誘導体
AU2006290802B2 (en) 4-amino-thieno[3,2-c]pyridine-7-carboxylic acid derivatives
CN101553456A (zh) 脂氧素a4类似物的晶体钾盐
JP2695852B2 (ja) 薬剤組成物
JPWO2020092823A5 (fr)
MXPA01000133A (en) Salts of paroxetine
KR100338999B1 (ko) 고지혈증치료제
KR20080015788A (ko) ＧｌｙＲ의 조정제 또는 아고니스트인 벤조산 유도체

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99810197.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 140385

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 49039/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 509077

Country of ref document: NZ

Ref document number: 09720152

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1999932772

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20242000

Country of ref document: SK

WWE Wipo information: entry into national phase

Ref document number: PV2000-4923

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 1020007015100

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2336470

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001/00020

Country of ref document: ZA

Ref document number: 200100020

Country of ref document: ZA

Ref document number: 2001/00055

Country of ref document: TR

ENP Entry into the national phase

Ref document number: 2000 558095

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/000133

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 1999 105204

Country of ref document: BG

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 200100098

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 1999932772

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020007015100

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2000-4923

Country of ref document: CZ

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999932772

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: PV2000-4923

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 1020007015100

Country of ref document: KR